- Authors: Zhao Y. et al.
- Year: 2021
- Journal: Eur J Pharmacol
- Applications: in vivo / siRNA / in vivo-jetPEI
- The in vivo jetPEI (Polyplus; France)/FPR2 siRNA or scrambled siRNA complexes were prepared by mixing equal volumes of diluted in vivo jetPEI (36 μl) and FPR2 siRNA or scrambled siRNA (300 μg) solutions according to the manufacturer's protocol. - The in vivo jetPEI/FPR2 siRNA or scrambled siRNA was i.p. injected 30 min prior to RvD1 treatment (n = 8). - The behavior of the rats in each group was observed daily, the esophagus was excised for histopathological assessment and immunohistochemical (IHC) staining, and primary rat esophageal epithelial cells (REECs) were isolated for WB analysis.
The role of resolvin D1 (RvD1) in gastroesophageal reflux disease (GERD) remains largely unknown. Here, we investigated the potential role of RvD1 in acid-induced DNA damage in esophageal epithelial cells, patients with refractory GERD and a rat model of acid reflux. Weak acid exposure induced longer comet tails, reactive oxygen species (ROS) generation, oxidative DNA damage and DNA double-strand breaks (DSBs) in cells and RvD1 (0.1 μM) blocked all these effects. Mechanistic analyses showed that apart from ROS-reducing effects, RvD1 possessed a strong capacity to promote DNA damage repair, augmenting cell cycle checkpoint activity and DSB repair by modulating phosphatase and tensin homolog (PTEN) in cells. We also detected the surface expression of formyl peptide receptor 2 (FPR2), a receptor for RvD1, in the esophageal epithelial cells, and inhibition of FPR2 abrogated the protective effects of RvD1 on cells. Furthermore, a positive correlation between RvD1 and PTEN was observed predominantly in the esophageal epithelium from patients with refractory GERD (r = 0.67, P < 0.05). Additionally, RvD1 administration upregulated PTEN, suppressed DNA DSBs and alleviated microscopic damage in the rat model of gastric reflux. FPR2 gene silencing abolished the therapeutic effects of RvD1 on the rat model. Taken together, RvD1 binding to FPR2 protects the esophageal epithelium from acid reflux-induced DNA damage via a mechanism involving the inhibition of ROS production and facilitation of DSB repair. These findings support RvD1 as a promising approach that may be valuable for the treatment of GERD.